Independent multi-center trial shows that Getinge’s NAVA ventilation mode shortens time of mechanical ventilation by almost 35% for adult ICU patients
The clinical effectiveness of Getinge’s patented Neurally Adjusted Ventilatory Assist (NAVA), which uses the patient’s own respiratory drive to control ventilator assistance, is supported in the NAVIATOR trial. According to the NAVIATOR trial, NAVA significantly increased the number of ventilator-free days and shortened the time of mechanical ventilation (MV) for adult patients with acute respiratory failure (ARF)[1].“This large multi-center independent trial supports that NAVA has significant positive clinical effects for adult patients in intensive care units (ICU). The study showed that